Fig. 2From: The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancerThe anti-tumor effect of anti-PD-L1 treatment was undermined by the enhanced immunosuppression in tumor. A The anti-PD-L1 treatment schedule in syngeneic tumor mouse model. 3 × 106 U14 cervical cells was subcutaneously injected on the flank of 7-weeks C57BL/6 mouse. Anti-PD-L1 (200 μg/time/mouse) was intraperitoneally injected in mouse seven days post tumor challenge, and five injection were performed. B The representative picture of tumors after five times anti-PD-L1 therapy. The tumor was numbered with Arabic numerals. C The HE dying for the tumors in figure (B), and the red arrow represents the necrosis area. The pictures were magnified for 400 times. Scale bar: 50 μm. D The mRNA level of immunosuppressive molecular, including CD206, Ly6C, Ly6G, Foxp3, and Arginase in control (no PD-L1 treatment), tumor ⑤ and tumor ⑥Back to article page